BiLD: finding new ways to measure how well chemotherapy works in lymphoma

This study is now closed. It is no longer recruiting participants.

Purpose of study

The aim of the study is to develop a blood test that would tell doctors how well chemotherapy for lymphoma is working. Biomarkers are substances in the blood that can give doctors information about a disease or treatment. In this study, the researchers take blood samples from people with lymphoma who are having chemotherapy, to look for new biomarkers. They test if they can use MRI scans along with the blood biomarkers to see how well chemotherapy is working.

What is involved

There is no treatment as part of this study. To enter, you must be due to have chemotherapy as part of your lymphoma treatment. The researchers need to take blood samples from you:

  • before you start chemotherapy and before each treatment
  • a week after you first started chemotherapy at the end of your chemotherapy course
  • every 3 months for 2 years or until your lymphoma comes back (relapses).

You also have an additional MRI scan before, during and after your chemotherapy course. If you can’t have an MRI scan (for example, because you have a pacemaker or a metal implant), you can still join the study but you won’t be included in this part.

The researchers also need a DNA sample from you, which they get from your spit. They will ask your doctor for a sample of lymphoma tissue taken when you had a biopsy.

Who can enter

Your consultant can give you advice on whether this trial might be suitable for you.

Around 50 people are needed for this study.

You may be able to enter if:

  • You have any type of lymphoma.
  • You are due to have chemotherapy for your lymphoma (this may be after diagnosis or if lymphoma has come back following earlier treatment).
  • You are 18 or over.

You will not be able to enter if:

  • You are pregnant or breastfeeding.

Further information

More information about this study is available at Cancer Research UK.